DR ISABEL GONZALEZ

Director

Dr Isabel Gonzalez has over 30 years of research experience, resulting in more than 50 publications in peer reviewed journals and book chapters. She combines 12 years experience in University research laboratories and 20 years of experience in the pharmaceutical industry, in three different multinational companies (Parke-Davis/Pfizer, Novartis and GSK) and one biotechnology company (Proximagen, currently BenevolentAI), where she was Head of Biology for the last 9 years. Isabel specialises in the areas of pain, inflammation and neurodegeneration and she has been a successful project leader, with a proven track record of achievements in several programme leadership roles across all these organisations. In her latest role at Proximagen Isabel was responsible for the scientific integrity of the biological work, timely delivery of objectives and development of the team, in charge of scientific direction with relation to biological sciences and expert input into all programme teams at Proximagen, covering all stages from exploratory through discovery and into clinical phases. Key contributor of scientific assessment of business development opportunities, due diligence and external presentations to potential partners of internal assets. Responsibility to identify, monitor and present studies run by CROs in a variety of different therapeutic areas. Deep knowledge of all Home Office licences and regulations. Isabel is a Graduate of the Universidad Complutense, Madrid (Spain) where she studied biology and completed a PhD in Animal Physiology in 1990.

 

©2019 DRUG DISCOVERY AND DEVELOPMENT CONSULTANTS LTD. TRADING AS 3D CONSULTANTS. REGISTERED IN ENGLAND AND WALES, COMPANY NUMBER 11438683